Ribavarin: Difference between revisions
| Line 19: | Line 19: | ||
==Contraindications== | ==Contraindications== | ||
*Allergy to class/drug | *Allergy to class/drug | ||
*Autoimmune hepatitis | *[[Autoimmune hepatitis]] | ||
*Coadministration with didanosine | *Coadministration with didanosine | ||
*Hemoglobinopathy (e.g. thalassemia, sickle cell) | *Hemoglobinopathy (e.g. [[thalassemia]], [[sickle cell]]) | ||
*Pregnant or potentially pregnant women, men who may impregnate someone | *[[Pregnant]] or potentially pregnant women, men who may impregnate someone | ||
*Renal impairment (CrCl <50) | *Renal impairment (CrCl <50) | ||
Revision as of 17:56, 29 September 2016
Administration
- Type: Antiviral- FDA approved for Hepatitis C, severe RSV infection. Off-label use: herpes simplex, influenza, viral hemorrhagic fever
- Dosage Forms: 200 tab, 200 cap
- Routes of Administration: Oral, inhalation
- Common Trade Names: Copegus, Rebetol, Ribasphere
Adult Dosing
- 200-1000mg daily (dose depends on genotype and concurrent treatment with interferon)
Pediatric Dosing
- Hep C: >2 years old: 15mg/kg daily OR 400-1200mg daily
- RSV (severe cases): 20mg/ml aerosolized over 12-18 hours x 3-7 days
Special Populations
- Pregnancy Rating: X
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing: reduced doses for mild-moderate impairment, do not use if CrCl <50
Contraindications
- Allergy to class/drug
- Autoimmune hepatitis
- Coadministration with didanosine
- Hemoglobinopathy (e.g. thalassemia, sickle cell)
- Pregnant or potentially pregnant women, men who may impregnate someone
- Renal impairment (CrCl <50)
Adverse Reactions
Serious
- Hemolytic anemia, TTP
- Bacterial disease
- Hepatotoxicity
- MI
- Suicide
Common
- Neutropenia
- Nausea, vomiting, diarrhea
- Asthenia, dizziness, fatigue
- Weight loss
- Pruritus
Pharmacology
- Half-life: ~300 hours
- Metabolism:
- Excretion: Mostly renal
Mechanism of Action
- Mechanism not well understood